A5024676209- Tuberous Sclerosis Complex Research
- Eosinophilic Disorders and Syndromes
- Corporate Governance and Law
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Drug-Induced Hepatotoxicity and Protection
- Mast cells and histamine
- Toxin Mechanisms and Immunotoxins
- Dermatology and Skin Diseases
- Birth, Development, and Health
- Renal and related cancers
- Polyamine Metabolism and Applications
- Herbal Medicine Research Studies
University of Cincinnati
2022-2025
University of Cincinnati Medical Center
2023
Abstract Lymphangioleiomyomatosis (LAM) is a cystic lung disease that primarily affects women, with an estimated global prevalence of 19 per million women. LAM caused by the invasion metastatic smooth muscle-like cells into parenchyma, leading to abnormal cell proliferation and progressive respiratory failure. have TSC gene mutations, which occur sporadically or in people Tuberous Sclerosis Complex. Although it known hyperactivation mechanistic target rapamycin complex 1 (mTORC1) due TSC2...
Lymphangioleiomyomatosis (LAM) is a rare, progressive lung disease that predominantly affects women. LAM cells carry
Tuberous sclerosis complex (TSC) is characterized by multisystem, low-grade neoplasia involving the lung, kidneys, brain, and heart. Lymphangioleiomyomatosis (LAM) a progressive pulmonary disease affecting almost exclusively women. TSC LAM are both caused mutations in TSC1 TSC2 that result mTORC1 hyperactivation. Here, we report single-cell RNA sequencing of lungs identified activation genes sphingolipid biosynthesis pathway. Accordingly, expression acid ceramidase (ASAH1) dihydroceramide...
ABSTRACT Lymphangioleiomyomatosis (LAM) is a cystic lung disease that primarily affects women. LAM caused by the invasion of metastatic smooth muscle-like cells into parenchyma, leading to abnormal cell proliferation, remodeling and progressive respiratory failure. have TSC gene mutations, which occur sporadically or in people with Tuberous Sclerosis Complex. Although it known hyperactivation mechanistic target rapamycin complex 1 (mTORC1) due TSC2 mutations contributes aberrant growth lung,...
Lymphangioleiomyomatosis (LAM) is a rare lung disease that exclusively affects premenopausal women. LAM caused by infiltration of metastasizing atypical smooth muscle-like cells into the lungs leading to progressive respiratory failure. Though origin these remains elusive, carry loss-of-function mutations in Tuberous Sclerosis Complex (TSC1/TSC2) genes, hyperactivation mechanistic target rapamycin complex 1 (mTORC1) and aberrant cell growth. There no cure for LAM. The greatest barriers...
ABSTRACT Lymphangioleiomyomatosis (LAM) is a rare, debilitating lung disease that predominantly affects women of reproductive age. LAM characterized by the infiltration lungs abnormally proliferating smooth muscle-like cells unknown origin via an estrogen-dependent metastatic mechanism. carry deleterious mutations tuberous sclerosis complex (TSC1/TSC2) genes, resulting in hyperactivation mechanistic target rapamycin 1 (mTORC1) and ultimately dysregulated cell growth. Sirolimus, FDA approved...